NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
Category
- Genetic/Familial High-Risk Assessment
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 6.2023
Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas.
Category
- Non-Hodgkin's Lymphoma
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
- Management of Immunotherapy-Related Toxicities
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy
Consolidation therapy is a critical component of ALL therapy, with the goal of eliminating any leukemic cells potentially remaining after induction therapy, further eradicating residual disease. MRD assessment is an essential component of the evaluation of response to therapy in ALL.
Category
- Acute Lymphoblastic Leukemia
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors
The field of genomics in myeloid malignancies and related implications in AML are evolving rapidly, and induction treatment strategies are now often guided by biological disease factors and fitness for intensive induction therapy. Familiarity with up-to-date risk stratification and targeted therapies is essential when formulating induction treatment strategies for newly diagnosed AML.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies
A better understanding of the pathogenesis of hematologic malignancies has led to the identification of new cytogenetic and molecular markers that distinguish between the various subtypes of hematologic malignancies. Informing hematologists and oncologists about the updated WHO5 classification and the new ICC will aid in the accurate diagnosis and development of a treatment plan to the specific subtype of hematologic malignancy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Case Studies in the Management of Leukemia
As a result of the therapeutic advances and clinical research affecting the management of patients with leukemia, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma is a challenging disease state to treat and there are now numerous approved agents for this patient population. Clinicians would greatly benefit from additional education on the available agents and their place in therapy given the different modalities of treatment employed in relapsed/refractory disease.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation